Investigational drug slows metastatic breast cancer progression
 

Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.Licensed from Medwire news with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.



More...